Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Teplizumab Shows Some Results in Phase 3 Study

By Drug Discovery Trends Editor | July 15, 2011

MacroGenics, Inc. announced results from Protégé, a Phase 3 clinical study of teplizumab in type 1 diabetes.

Exploratory, post-hoc analyses suggest that when used in a 14-day full dose regimen, teplizumab, an anti-CD3 monoclonal antibody, preserves C-peptide and increases the percentage of patients requiring very low doses of insulin with good glycemic control (glycosylated hemoglobin) compared to placebo.

In addition, these analyses revealed that certain subpopulations may be more likely to respond to teplizumab treatment.
 
Protégé is a two-year, randomized, double-blind, placebo-controlled clinical trial, with 513 patients aged 8 to 35, recently diagnosed with type 1 diabetes, who were enrolled and treated at 83 clinical centers in North America, Europe, Israel, and India.

Participants were allocated to receive daily infusions of teplizumab (full dose for 14 days, one-third dose for 14 days, or full dose for 6 days) or placebo at baseline and at 6 months.

 The primary composite endpoint of the Protégé study was the percentage of patients with insulin use at one year. Although teplizumab was shown to have an acceptable safety profile, the primary endpoint was not achieved, as had been previously announced in a joint communication with Eli Lilly and Company in October 2010. Protégé is ongoing and will complete the two-year follow-up in 2011.
 
 A greater proportion of patients in the teplizumab groups were able to discontinue or use very low doses of insulin compared to the placebo group. A reduced insulin requirement while maintaining glycemic control appears to support teplizumab having a biological effect.
 
“Although the Protégé study missed its primary endpoint, the data appear to indicate that teplizumab has a desired biological effect in certain subpopulations with a potentially meaningful therapeutic benefit for patients with recent-onset type 1 diabetes,” says Scott Koenig, president and CEO of MacroGenics. “These groups include patients for whom treatment is begun ? 6 weeks after diagnosis and in children 8 to 11 years old.”

The findings were published in The Lancet.

Release Date: June 28, 2011
Source: MacroGenics, Inc. https://www.macrogenics.com/press_releases-298.html


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE